The FDA approved the complement C5 inhibitor crovalimab (Piasky) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening blood disease. Indicated for PNH in adults and ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease that can cause fatigue due to anemia. PNH is closely associated with fatigue due to a loss of red blood cells, leading to anemia. This ...

An AstraZeneca drug acquired in a $930 million deal has received FDA approval as a treatment for a rare blood disorder. In this disease, paroxysmal nocturnal hemoglobinuria (PNH), a part of the immune ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. I think there's still work that needs to be ...

Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The ...

The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and haemolysis control in people with paroxysmal nocturnal hemoglobinuria (PNH) 1 COMMODORE 3 is the first ...

Healio spoke with Marcel P. Devetten, MD, associate professor of oncology and hematology at University of Nebraska Medical Center, about multidisciplinary care in paroxysmal nocturnal hemoglobinuria ...

Diagnosed at a young age with a rare and potentially life-threatening disease, one man learned the power of taking control. When South Carolinian Roger was diagnosed with paroxysmal nocturnal ...

A month after Novartis made its entry into the paroxysmal nocturnal haemoglobinuria (PNH) field, AstraZeneca’s newest contender Voydeya bolsters the company’s presence in the disease area with a world ...

New, long-term data for VOYDEYA™ as add-on to ULTOMIRIS® or SOLIRIS® will show low rate of breakthrough hemolysis events and sustained improvements in quality-of-life measures in PNH with ...